Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from TrivarX Limited ( (AU:TRI) ) is now available.
TrivarX Limited has made significant advancements in its clinical trial aimed at screening for major depressive episodes among veterans, in collaboration with the US Department of Veterans Affairs and GLAVREF. The trial, which uses TrivarX’s proprietary ECG-based technology, has shown promising interim results, reinforcing the company’s commitment to providing scalable mental health screening solutions. Additionally, TrivarX is expanding its diagnostic portfolio by acquiring the Stabl-Im IP, a transformative imaging technology for early brain tumor detection, marking a strategic move into the high-growth neuro-oncology market. This expansion is supported by a successful $4.2 million placement, indicating strong investor confidence in TrivarX’s strategic direction and technological capabilities.
More about TrivarX Limited
TrivarX Limited operates in the healthcare industry, focusing on developing innovative diagnostic technologies. The company specializes in mental health and neuro-oncology diagnostics, utilizing non-invasive, AI-driven tools to enhance early detection and treatment strategies.
YTD Price Performance: 37.50%
Average Trading Volume: 3,978,659
Technical Sentiment Signal: Hold
Current Market Cap: A$15.56M
For detailed information about TRI stock, go to TipRanks’ Stock Analysis page.